Jacqueline von Salm

Company: Psilera Bioscience

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Streamlining Translation of a Next-Generation Psilocybin Derivative to Reduce Behavioural Symptoms Associated with FTD 12:00 pm

Expanding our understanding of non-SSRI serotonergics for symptom management of Frontotemporal Dementias (FTD) Presenting the effects of a non-hallucinogenic psilocybin derivative, PSIL-006, on translational biomarkers for neuroinflammation and neuroplasticity In vivo mouse models for neurodegeneration and psychiatric symptomology including compulsive behaviors, circadian rhythm, and apathyRead more

day: Track 2 AM Day 2